N
Nagahiro Saijo
Researcher at AstraZeneca
Publications - 386
Citations - 31129
Nagahiro Saijo is an academic researcher from AstraZeneca. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 65, co-authored 386 publications receiving 28187 citations. Previous affiliations of Nagahiro Saijo include Harvard University.
Papers
More filters
Journal ArticleDOI
P2-274: Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC)
Kaoru Kubota,Tomohide Tamura,Nobuyuki Yamamoto,Kazuhiko Nakagawa,Satoshi Morita,Yoshihiro Nambu,S. Adachi,Yutaka Nishiwaki,Nagahiro Saijo,Masahiro Fukuoka +9 more
Journal ArticleDOI
Growth-Stimulating Pathways in Lung Cancer: Implications for Targets of Therapy
Ikuo Sekine,Nagahiro Saijo +1 more
TL;DR: Phase I studies of epidermal growth factor-receptor inhibitors demonstrate objective responses without severe toxicity as single agents in patients with non-small-cell lung cancer refractory to conventional chemotherapy, which might lead to breakthroughs in the treatment of lung cancer with distant metastases not curable by conventional chemotherapy alone.
Journal ArticleDOI
Activation-induced apoptosis of peripheral lymphocytes treated with 7-hydroxystaurosporine, UCN-01.
Hisao Fukumoto,Tomohide Tamura,Yoshikazu Kamiya,Jitsuo Usuda,Toshihiro Suzuki,Fumihiko Kanzawa,Hyo-Jeong Kuh,Yuichiro Ohe,Nagahiro Saijo,Kazuto Nishio +9 more
TL;DR: Lymphocyte depletion mediated byactivation-induced apoptosis is likely to occur in patient treated with UCN-01 at high doses, and some specific inhibitory factor(s) in human serum may antagonize the lympholytic effect of UCn-01.
Journal ArticleDOI
Bacterial Meningitis Observed in a Phase I Trial of Vinorelbine, Cisplatin and Thoracic Radiotherapy for Non-small Cell Lung Cancer: Report of a Case and Discussion on Dose-limiting Toxicity
Ikuo Sekine,Takahisa Matsuda,Toshimitsu Saisho,Hirokazu Watanabe,Noboru Yamamoto,Hideo Kunitoh,Yuichiro Ohe,Tomohide Tamura,Tetsuro Kodama,Nagahiro Saijo +9 more
TL;DR: A 66-year-old male with adenosquamous carcinoma of the lung, cT2N3M0, stage IIIB, was enrolled in a phase I trial of chemoradiotherapy and diagnosed with bacterial meningitis, which developed in this case without any associated decrease in the peripheral blood leukocyte count.
Journal ArticleDOI
Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
Tetsu Shinkai,Nagahiro Saijo,Keigo Tominaga,Kenji Eguchi,Shimizu E,Yasutsuna Sasaki,Jiro Fujita,Hitoyasu Futami,Akio Hoshi +8 more
TL;DR: Myelosuppression, primarily thrombocytopenia, was pronounced with either treatment regimen and it was the major dose-limiting toxicity.